Efficacy of ibandronate: A long term confirmation

Clinical Cases in Mineral and Bone Metabolism

Volumn 7, Issue 1, 2010, Pages 23-26

  Di Munno, Ombretta ^a   Delle Sedie, Andrea ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bisphosphonates; Fracture; Ibandronate; Long term efficacy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID;

BONE DENSITY; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RISK REDUCTION; SHORT SURVEY; SOCIOECONOMICS; VERTEBRA FRACTURE;

EID: 77953312178     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (40)

1. Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
2. Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:849-68.
3. Geusens PP, Roux CH, Reid DM et al. Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence - based clinical perspective. Nat Clin Pract Rheumatol 2008;4:240-8.
4. Boonen S, Kay R, Cooper C et al. Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. Int J Clin Pract 2009;63:1792-804.
5. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60. (Pubitemid 41368578)
6. Sebaldt OI, Shane LG, Pham B et al. Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonates therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15(Suppl 1):S107.
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8. (Pubitemid 40064656)
8. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug;81(8):1013-22.
9. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122(2 Suppl):S3-13.
10. Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006;1:415-23.
11. Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21. (Pubitemid 43781506)
12. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61. (Pubitemid 40911458)
13. Papapoulos SE. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int J Clin Pract 2003;57:417-22.
14. Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
15. Chesnut III CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9. (Pubitemid 41094364)
16. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005;37:651-4.
17. Ettinger MP, Felsenberg D, Harris ST et al. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol 2005;32:1968-74. (Pubitemid 41429028)
18. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22. (Pubitemid 41033514)
19. Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61.
20. Felsenberg D, Czerwinski E, Stakkestad J, Neate C, Masanauskaite D, Reginster JY. Efficacy of monthly oral Ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporos Int 2009;20(Suppl 1):S5-22.
21. Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46. (Pubitemid 43877933)
22. Eisman JA, Civitelli R, Adami S et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488-97. (Pubitemid 351374427)
23. Bianchi G, Felsenberg D, Czerwinski E. Efficacy of i.v. Ibandronate is maintained over 5 years: the DIVA LTE study. Ann Rheum Dis 2009;68(Suppl3):494.
24. Cranney A, Wells GA, Yetisir E et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-7.
25. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of nonvertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45.
26. rd et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-9.
27. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 2009;44:423-7.
28. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13.
29. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34.
30. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 2009;20:973-8.
31. Harris ST, Reginster JY, Harley C et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009;44:758-65.
32. Silverman SL, Cramer JA, Sunyec Z et al. Women are more persistent with monthly bisphosphonates therapy compared to weekly bisphosphonates: 12-Month results from 2 retrospective databases. J Bone Miner Res 2007;22(Suppl 1):S454.
33. Emkey R, Koltun W, Beusterien K et al. Patient preference for once-monthly ibandronate versus once-weekly alendronato in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903.
34. Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905.
35. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010;21(1):145-55.
36. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008;30(4):605-21.
37. Lewiecki EM, Keaveny TM, Kopperdahl DL et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009;94:171-80.
38. Recker RR, Ste-Marie LG, Langdahl B et al. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: The DIVA study. Bone 2009 Nov 10. [Epub ahead of print]
39. Hernandez CJ, Keaveny TM. A biomechanical perspective on bone quality. Bone 2006;39:1173-81.
40. Bonnick SL. HSA: beyond BMD with DXA. Bone 2007;41(1 Suppl 1):S9-12.